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Background/aim: Determining the severity of systemic sclerosis related interstitial lung disease (SSc-ILD) is based on clinical and
radiological findings, inflammation marker levels, and carbon monoxide diffusing capacity of the lung (DLCO). Recently studies are
ongoing for objective and easy markers. Neutrophil/lymphocyte ratio (NLR) is shown to be a good marker for inflammation in recent
clinical trials. In this study, we aimed to identify the possible relationship between NLR and carbon monoxide transfer coefficient (KCO)
of SSc-ILD patients.
Materials and methods: Fifty-nine patients with systemic sclerosis (SSc) were enrolled in the study. We used high-resolution computed
tomography for diagnosis and used DLCO to evaluate degree of lung involvement. Complete blood cell counts and acute phase reactants
were included as laboratory assessments.
Results: NLR values were significantly higher in the SSc-ILD group (3.66 ± 1.32 vs. 2.85 ± 1.12, P = 0.01) and correlated negatively with
KCO. The NLR cut-off value was 3.21, its sensitivity was 81%, and its specificity was 81%.
Conclusion: NLR level may serve as a marker of lung involvement in the presence of ILD in patients with SSc.
Key words: Inflammation, neutrophil/lymphocyte ratio, systemic sclerosis, interstitial lung disease

1. Introduction
Systemic sclerosis (SSc) is an autoimmune disease that can
potentially affect gastrointestinal, renal, cardiovascular,
and pulmonary systems by disease-specific autoantibodies
and overproduction of collagen (1). Although pulmonary
thromboembolic disease, aspiration pneumonitis,
pleural disease, airways disease, lung cancer, and druginduced pneumonitis might also be seen, interstitial lung
disease (ILD) is the most common and worrisome lung
involvement form of SSc (2).
Erythrocyte sedimentation rate (ESR) and C-reactive
protein (CRP) level are commonly used biomarkers of
the inflammatory response status in patients with SSc.
CRP level is elevated in one-quarter of SSc patients,
especially at the onset of the disease (3). It is correlated
with disease activity, severity, poor pulmonary function,
and shorter survival (3). Recent studies showed that
neutrophil/lymphocyte ratio (NLR) is also a marker of
inflammation such as CRP and ESR (4). Carbon monoxide
transfer coefficient (KCO) is an important indicator of
parenchymal destruction and shows the rate of uptake
* Correspondence: gozdeyildirimcetin@gmail.com

of carbon monoxide (CO) from alveolar gas. The aim of
the present study was to investigate possible relationships
between NLR and KCO in systemic sclerosis related
interstitial lung disease (SSc-ILD) patients.
2. Materials and methods
This study was designed and performed in the Department
of Rheumatology of the Kahramanmaraş Sütçü İmam
University Faculty of Medicine, Turkey. In total, 82
SSc patients were retrospectively screened. Exclusion
criteria were active infection, and the presence of any
hematological (included anemia), cardiovascular, and
metabolic disorders. Thus we excluded 23 patients, and 59
patients were enrolled in the study. SSc-ILD was present
in 34 of them and there was no pulmonary involvement
in the remaining 25. We compared the groups with and
without lung involvement.
Venous blood was drawn from each patient into
tubes with and without anticoagulant. The standard
laboratory workup included counts of white blood cells
(WBC), neutrophils (NEU), and lymphocytes (LYM), and
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calculation of the NLR. ESR was measured immediately
after blood collection. CRP levels were measured by
nephelometric methods.
High resolution computed tomography (HRCT) was
used for the diagnosis of ILD. Ground-glass opacification
and honeycomb reticular shadowing were accepted as
ILD. We used the diffusing capacity of the lungs for carbon
monoxide (DLCO) and KCO to evaluate the degree of ILD.
A value ≥ 81 for DLCO and KCO is considered normal (5).
Student’s t-test was used for comparison of averages.
Correlations among variables were assessed by Pearson’s
correlation testing. A P-value < 0.05 was considered to
indicate a significant difference. ROC analysis was used
for determining the cut-off value of the NLR.
3. Results
Thirty-four SSc patients with ILD and 25 SSc patients
without ILD as a control group were enrolled in the present
study. The demographics and clinical and laboratory
characteristics of the patients and controls are summarized
in Table 1. There were 25 female and 9 male patients in
the ILD group and 19 female and 6 male patients in the
Table 1. Sociodemographic attributes
characteristics of patients with SSc.

and

laboratory

SSc patients (n=59)
Age (years), mean ± SD

48 ± 12.7

Sex (M/F)

15/44

Age at onset of SSc (years)

40 ± 14.5

Disease duration (years), mean ± SD

3.7 ± 2.6

WBC count (K/µL), mean ± SD

7395 ± 1697

Hb count (g/dL), mean ± SD

13.4 ± 1.33

PLT count (K/µL), mean ± SD

306 ± 78

NLR, mean ± SD

3 ± 1.2

ESR (mm/h), mean ± SD

28 ± 19.4

CRP value (mg/dL), mean ± SD

4.7 ± 7.9

SSc, systemic sclerosis; SD, standard deviation; WBC, white
blood cell; Hb, hemoglobin; PLT, platelets; NLR, neutrophil to
lymphocyte ratio; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate.

control group (P = 0.08). The median disease duration in
the ILD and control groups was 4.3 ± 2.3 and 3.1 ± 2.9
years, respectively (P = 0.88). There was no statistically
significant difference between the two groups with regard
to sex, age, or disease duration.
White blood cell (WBC) counts of the ILD and
control groups were 7576 ± 1715 and 7262 ± 1697 K/µL
respectively (P = 0.48). Mean hemoglobin (Hb) values
were 13.3 ± 0.9 g/dL in the ILD group and 13.5 ± 1.5 g/dL
in the control group (P = 0.53). Mean platelet counts (PLT)
were 306 ± 78 K/µL in the ILD group and 305 ± 95 K/µL
in the control group. SSc patients with and without ILD
had similar WBC, Hb, and PLT counts. The mean NLR
of the ILD and control patients was 3.6 ± 1.35 and 2.8 ±
1.08, respectively, using Student’s t-test (P = 0.001). The
serum NLR of ILD patients was significantly higher than
that of the controls. We used Student’s t-test for comparing
the groups (KCO ≥ 81 vs. KCO ≤ 80). The mean NLR of
patients with KCO ≥ 81 and KCO ≤ 80 was 2.11 ± 0.8 and
4.05 ± 1.48, respectively (P = 0.00).
The correlation analysis between NLR and ESR, CRP,
DLCO, and KCO is summarized in Table 2. There was no
significant difference between the ILD and control groups
with regard to ESR (P = 0.07) or DLCO (P = 0.3) values.
NLR values correlated negatively with the KCO values (P =
0.04, r = −0.32) and correlated positively with CRP values
of SSc patients (P = 0.04, r = 0.32) (Table 3). ROC analysis
was done for determining NLR cut-off level and found to
be 3.21; its sensitivity was 81% and specificity was 81%
(Figure).
4. Discussion
The main finding of our study relates to the identification
of the NLR as a novel noninvasive marker of disease
severity in SSc-ILD. We showed that the NLR levels were
positively correlated with CRP and negatively correlated
with KCO.
HRCT is the standard method for noninvasive diagnosis
of SSc-ILD and can detect mild abnormalities. The HRCT
pattern seen in SSc patients is generally nonspecific
interstitial pneumonia (NSIP), with a greater proportion
of ground-glass opacities and a lower degree of coarse
reticulation. However, a usual interstitial pneumonia

Table 2. Correlation analysis between NLR and ESR, CRP, DLCO, and KCO values.

NLR

CRP value (mg/dL)

ESR (mm/h)

DLCO

KCO

r value

0.32

0.28

-0.16

-0.32

P value

0.04

0.07

0.3

0.04

NLR, neutrophil to lymphocyte ratio; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; DLCO, transfer factor of the lung
for carbon monoxide; KCO, coefficient factor of the lung for carbon monoxide.
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Table 3. NLR values for SSc-ILD patients according to KCO.
NLR
KCO

≤80

4.05 ± 1.48

≥81

2.11 ± 0.8

P value
0.00

NLR, neutrophil to lymphocyte ratio; KCO, coefficient factor of
the lung for carbon monoxide.

Figure. ROC analysis for NLR cut-off value.
NLR, neutrophil to lymphocyte ratio

(UIP) pattern and honeycomb cysts can also be seen (6).
Although forced vital capacity (FVC) and DLCO are both
identified as prognostic markers in SSc-ILD, a declining
DLCO is the single most significant marker of poor
outcome and correlates with the extent of lung disease on
HRCT (7). The DLCO measures the capacity of the lungs
to transfer gas from air to the red blood cells in pulmonary
capillaries. The DLCO test is more convenient and easier
and takes less time than spirometric tests and there are
no contraindications or adverse effects. Because of these
reasons we use DLCO for follow-up of SSc-ILD patients
in our clinic.
The value calculated from DLCO/alveolar volume
(VA) is related to Krogh’s constant, K, and for this reason
DLCO/VA is also known as KCO. KCO is useful for
distinguishing the reason for total lung capacity (TLC)

decrease as intraparenchymal or extraparenchymal. This
means that when TLC is reduced but the lung tissue is
normal, which would be the case with neuromuscular
diseases or chest wall diseases, then KCO should be
increased. Interstitial involvement in restrictive lung
disease is often complicated and there can be multiple
reasons for a decrease in DLCO. Scarring and a loss of
elasticity cause the lung to become stiffer and harder to
expand, which decreases TLC. The alveolar membrane
can thicken, which increases resistance to the transfer
of gases. Moreover, probably, most commonly there is
destruction of the alveolar capillary bed, which decreases
the pulmonary capillary blood volume and the functional
alveolar capillary surface area. This means that when TLC
is reduced and there is interstitial involvement, a normal
KCO (in terms of percent predicted) is actually abnormal.
The components of DLCO (KCO and VA) may largely vary
in ILD while DLCO appears constant. The magnitudes
of KCO and VA values might indicate distinct disease
mechanisms and thereby bear a relative prognostic value
in addition to giving clues to the pathogenesis of these
diseases. There are several studies confirming clinicians
should take into account not only DLCO but also VA and
KCO when seeking to assess ILD (8). Because of its high
sensitivity in ILD we used KCO in our study.
Both ESR and CRP are acute-phase reactants.
CRP is produced by hepatocytes upon stimulation by
interleukin-6 (IL-6) and has been utilized as a marker of
infection and inflammation (9). ESR is a biomarker for
increased morbidity and mortality in SSc (10,11). However,
data are limited about the impact of CRP associations with
SSc activity and severity. CRP level was found elevated in
35%–54% of Japanese patients with SSc in two studies,
but the sample size was small (40 patients in each study)
(12,13).
The current study showed that elevated CRP levels are
correlated with lung involvement rated according to KCO
in SSc-ILD.
The NLR, differentially (and readily) calculated from
complete blood count data, has recently been shown to
be a novel marker of infection and inflammation (14,15).
An increase in the NLR has been noted to be common
in patients with cancer, cardiovascular disease, active
rheumatoid arthritis, and active ulcerative colitis (16–19).
The present study had some limitations including the
cross-sectional design and the relatively small sample size;
SSc-ILD was not evaluated separately as honeycombing
and ground glass and our study was not designed to
elucidate the mechanistic pathways that lead to higher
NLR in patients with SSc.
In conclusion, NLR values can serve as useful markers
of SSc-ILD in the absence of a rise in the ESR and CRP
level.
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